{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:46:40Z","timestamp":1790729200444,"version":"4.1.0"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Cannabinoids relieve pain, nausea, anorexia and anxiety, and improve quality of life in several cancer patients. The immunotherapy with checkpoint inhibitors (ICIs), although very successful in a subset of patients, is accompanied by moderate to severe immune-related adverse events (ir-AE) that often necessitate its discontinuation. Because of their role in symptomatic relief, cannabinoids have been used in combination with immune checkpoint inhibitor (ICI) immunotherapy. A few studies strongly suggest that the use of medicinal cannabis in cancer patients attenuates many of the ir-AE associated with the use of ICI immunotherapy and increase its tolerability. However, no significant beneficial effects on overall survival, progression free survival or cancer relapses were observed; rather, some of the studies noted adverse effects of concurrent administration of cannabinoids with ICI immunotherapy on the clinical benefits of the latter. Because of cannabinoids\u2019 well documented immunosuppressive effects mediated through the cannabinoid recptor-2 (CB2), we propose considering this receptor as an inhibitory immune checkpoint\n                    <jats:italic>per se<\/jats:italic>\n                    . A simultaneous neutralization of CB2, concurrent with cannabinoid treatment, may lead to better clinical outcomes in cancer patients receiving ICI immunotherapy. In this regard, cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG), with little agonism for CB2, may be better therapeutic choices. Additional strategies e.g., the use of monoacylglycerol lipase (MAGL) inhibitors that degrade some endocannabinoids as well as lipogenesis and formation of lipid bilayers in cancer cells may also be explored. Future studies should take into consideration gut microbiota, CYP450 polymorphism and haplotypes, cannabinoid-drug interactions as well as genetic and somatic variations occurring in the cannabinoid receptors and their signaling pathways in cancer cells for personalized cannabis-based therapies in cancer patients receiving ICIs. This may lead to rational knowledge-based regimens tailored to individual cancer patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1497829","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:09:12Z","timestamp":1741140552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"MariaLuisa","family":"Vigano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"As\u2019sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Samarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia T.","family":"Costiniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know","volume":"9","author":"Lemiale","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"JCM"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121285","article-title":"Diversity of immune checkpoints in cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"B6","article-title":"Ipilimumab and cancer immunotherapy: A new hope for advanced stage melanoma","volume":"84","author":"Mansh","year":"2011","journal-title":"Yale J Biol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010179","article-title":"Metabolic implications of immune checkpoint proteins in cancer","volume":"11","author":"Stirling","year":"2022","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-016-0163-8","article-title":"5-fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers","volume":"4","author":"Van Der Kraak","year":"2016","journal-title":"J immunotherapy Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773168","article-title":"What happens to the immune microenvironment after PD-1 inhibitor therapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827921","article-title":"Biological characteristics and clinical significance of soluble PD-1\/PD-L1 and exosomal PD-L1 in cancer","volume":"13","author":"Niu","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921445117","article-title":"Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13956","article-title":"Tumour cell-intrinsic CTLA 4 regulates PD -L1 expression in non-small cell lung cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Medi"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.028","article-title":"Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity","volume":"32","author":"Kennedy","year":"2024","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19712","DOI":"10.1038\/s41598-021-99311-y","article-title":"Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): A phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.010","article-title":"Impact of acetaminophen on the efficacy of immunotherapy in cancer patients","volume":"33","author":"Bessede","year":"2022","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31627","article-title":"Toxicities and outcomes: do steroids matter","volume":"124","author":"Johnson","year":"2018","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15234","article-title":"Impact of corticosteroids use on efficacy of immune checkpoint inhibitors in cancer patients: A meta-analysis","volume":"38","author":"Li","year":"2020","journal-title":"JCO"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26092774","article-title":"Cannabinoids, phenolics, terpenes and alkaloids of cannabis","volume":"26","author":"Radwan","year":"2021","journal-title":"Molecules"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2020.22.3\/rmaldonado","article-title":"The endocannabinoid system in modulating fear, anxiety, and stress","volume":"22","author":"Maldonado","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42238-021-00062-4","article-title":"The biosynthesis of the cannabinoids","volume":"3","author":"Tahir","year":"2021","journal-title":"J Cannabis Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses","volume":"12","author":"Walsh","year":"2021","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/can.2022.0126","article-title":"The dark side of cannabidiol: the unanticipated social and clinical implications of synthetic \u03948 -THC","volume":"8","author":"Geci","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230623104624","article-title":"Hexahydrocannabinol pharmacology, toxicology, and analysis: the first evidence for a recent new psychoactive substance","volume":"21","author":"Graziano","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112361","article-title":"Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage","volume":"145","author":"Gonz\u00e1lez-Mariscal","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2020.573299","article-title":"Potentials and challenges of genomics for breeding cannabis cultivars","volume":"11","author":"Barcaccia","year":"2020","journal-title":"Front Plant Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/dta.407","article-title":"Cannabis - from cultivar to chemovar","volume":"4","author":"Hazekamp","year":"2012","journal-title":"Drug Testing Anal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2023.08.006","article-title":"Phytocannabinoids: pharmacological effects, biomedical applications, and worldwide prospection","volume":"13","author":"de Brito Siqueira","year":"2023","journal-title":"J Tradit Complement Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14982","article-title":"The neuropharmacology of cannabinoid receptor ligands in central signaling pathways","volume":"55","author":"Brunt","year":"2022","journal-title":"Eur J Neurosci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03232-8","article-title":"Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and \u03949-tetrahydrocannabinol: A pilot study","volume":"78","author":"Peters","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.130","article-title":"Circulating endocannabinoids: from whence do they come and where are they going","volume":"43","author":"Hillard","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002345","article-title":"Cannabinoids and inflammation: implications for people living with HIV","volume":"33","author":"Costiniuk","year":"2019","journal-title":"AIDS"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbi.2016.06.008","article-title":"Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation","volume":"59","author":"Shamran","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010038","article-title":"Identifying FAAH inhibitors as new therapeutic options for the treatment of chronic pain through drug repurposing","volume":"15","author":"Zanfirescu","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bcp.2018.07.036","article-title":"Monoacylglycerol lipase (MAGL) as a promising therapeutic target","volume":"157","author":"Gil-Ord\u00f3\u00f1ez","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110456","article-title":"Plasma endocannabinoidome and fecal microbiota interplay in people with HIV and subclinical coronary artery disease: results from the canadian HIV and aging cohort study","volume":"27","author":"Mboumba Bouassa","year":"2024","journal-title":"iScience"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.04.009","article-title":"Endocannabinoid and prostanoid crosstalk in pain","volume":"25","author":"Buisseret","year":"2019","journal-title":"Trends Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7812\/TPP\/19.200","article-title":"Mechanisms of action and pharmacokinetics of cannabis","volume":"25","author":"Chayasirisobhon","year":"2021","journal-title":"TPJ"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2013.4.4.7","article-title":"Basic review of the cytochrome P450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"JADPRO"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1055481","article-title":"Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions","volume":"13","author":"Smith","year":"2023","journal-title":"Front Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2008.01671.x","article-title":"Cannabinoid receptors: where they are and what they do","author":"Mackie","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10436","article-title":"Cannabinoid receptors and their relationship with chronic pain: A narrative review","volume":"12","author":"Anthony","year":"2020","journal-title":"Cureus"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14331","article-title":"Insights into the effects of the endocannabinoid system in cancer: A review","volume":"175","author":"Fraguas-S\u00e1nchez","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8825358","article-title":"Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: A comprehensive review","volume":"2023","author":"Singh","year":"2023","journal-title":"Behav Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094876","article-title":"The (Poly)Pharmacology of cannabidiol in neurological and neuropsychiatric disorders: molecular mechanisms and targets","volume":"22","author":"Vitale","year":"2021","journal-title":"IJMS"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.026","article-title":"Progress in brain cannabinoid CB2 receptor research: from genes to behavior","volume":"98","author":"Jordan","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.03.040","article-title":"Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area","volume":"42","author":"Ma","year":"2019","journal-title":"EBioMedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.9b00049","article-title":"Cannabinoid receptor 2 (CB 2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes","volume":"2","author":"Saroz","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815034116","article-title":"Therapeutic targeting of HER2\u2013CB 2 R heteromers in HER2-positive breast cancer","volume":"116","author":"Blasco-Benito","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0481","article-title":"Agonist-induced CXCR4 and CB2 heterodimerization inhibits G\u03b113\/rhoA-mediated migration","volume":"16","author":"Scarlett","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/jbcpp-2015-0080","article-title":"GPR55 - a putative \u201cType 3\u201d Cannabinoid receptor in inflammation","volume":"27","author":"Yang","year":"2016","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790980069","article-title":"GPR55: current knowledge and future perspectives of a purported \u201cType-3\u201d Cannabinoid receptor","volume":"17","author":"Moriconi","year":"2010","journal-title":"Curr Med Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051064","article-title":"THC reduces ki67-immunoreactive cells derived from human primary glioblastoma in a GPR55-dependent manner","volume":"13","author":"Kolbe","year":"2021","journal-title":"Cancers"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2009.07.001","article-title":"Receptors for acylethanolamides-GPR55 and GPR119","volume":"89","author":"Godlewski","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41398-024-02820-3","article-title":"GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice","volume":"14","author":"He","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","article-title":"Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity","volume":"111","author":"Rosenberg","year":"2023","journal-title":"Neuron"},{"key":"B75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/0929867311302010008","article-title":"GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors","volume":"20","author":"Gasperi","year":"2013","journal-title":"Curr Med Chem"},{"key":"B76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12974-018-1362-7","article-title":"Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells","volume":"15","author":"Saliba","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2329\/perio.63.11","article-title":"Expression of cannabinoid receptor GPR55 in human gingival fibroblasts and anti-inflammatory effects of cannabidiol via GPR55","volume":"63","author":"Mishiro","year":"2021","journal-title":"Nihon Shishubyo Gakkai Kaishi"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235918","article-title":"The cytotoxic effects of cannabidiol and cannabigerol on glioblastoma stem cells may mostly involve GPR55 and TRPV1 signalling","volume":"14","author":"Lah","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1248\/bpbreports.7.3_90","article-title":"Inositolphospholipids and GPR55","volume":"7","author":"Ito","year":"2024","journal-title":"BPB Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29061258","article-title":"Uncovering the power of GPR18 signalling: how rvD2 and other ligands could have the potential to modulate and resolve inflammation in various health disorders","volume":"29","author":"Honkisz-Orzechowska","year":"2024","journal-title":"Molecules"},{"key":"B81","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s42003-020-0964-7","article-title":"Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20","volume":"3","author":"Liu","year":"2020","journal-title":"Commun Biol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-023-01464-x","article-title":"TRP (Transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases","volume":"8","author":"Zhang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/biom13101557","article-title":"TRP channels in cancer: signaling mechanisms and translational approaches","volume":"13","author":"Marini","year":"2023","journal-title":"Biomolecules"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114074","article-title":"The role of transient receptor potential channels in metastasis","volume":"158","author":"Bai","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/bab.2119","article-title":"CBD activation of TRPV1 induces oxidative signaling and subsequent ER stress in breast cancer cell lines","volume":"69","author":"De La Harpe","year":"2022","journal-title":"Biotech App Biochem"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9965737","article-title":"TRPV1 channel activated by the PGE2\/EP4 pathway mediates spinal hypersensitivity in a mouse model of vertebral endplate degeneration","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxid Med Cell Longevity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J Neurosci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020774","article-title":"TRPV3: structure, diseases and modulators","volume":"28","author":"Su","year":"2023","journal-title":"Molecules"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00413","article-title":"TRPV4\u2014A missing link between mechanosensation and immunity","volume":"11","author":"Michalick","year":"2020","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091703","article-title":"Targeting TRPV4 channels for cancer pain relief","volume":"16","author":"Antoniazzi","year":"2024","journal-title":"Cancers"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1098448","article-title":"Therapeutic potential of TRPM8 channels in cancer treatment","volume":"14","author":"Ochoa","year":"2023","journal-title":"Front Pharmacol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.610873","article-title":"The TRPM8 protein is a testosterone receptor","volume":"290","author":"Asuthkar","year":"2015","journal-title":"J Biol Chem"},{"key":"B94","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ccell.2018.05.001","article-title":"Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance","volume":"33","author":"Takahashi","year":"2018","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111485","article-title":"VDAC1 at the intersection of cell metabolism, apoptosis, and diseases","volume":"10","author":"Shoshan-Barmatz","year":"2020","journal-title":"Biomolecules"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106683","article-title":"Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer","volume":"189","author":"Mahmoud","year":"2023","journal-title":"Pharmacol Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106603","article-title":"Cannabinoid-mediated targeting of mitochondria on the modulation of mitochondrial function and dynamics","volume":"187","author":"Malheiro","year":"2023","journal-title":"Pharmacol Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.141","article-title":"Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma","volume":"4","author":"Vara","year":"2013","journal-title":"Cell Death Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02096-8","article-title":"The role of PPAR\u03b3 in prostate cancer development and progression","volume":"128","author":"Hartley","year":"2023","journal-title":"Br J Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-019-00584-7","article-title":"Role of cannabinoid receptor 1 and the peroxisome proliferator-activated receptor \u03b1 in mediating anti-nociceptive effects of synthetic cannabinoids and a cannabinoid-like compound","volume":"27","author":"Alsalem","year":"2019","journal-title":"Inflammopharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2022.08.003","article-title":"Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies","volume":"33","author":"Ghasemi-Gojani","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"B103","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biochi.2018.06.016","article-title":"Serotonin and human cancer: A critical view","volume":"161","author":"Sarrouilhe","year":"2019","journal-title":"Biochimie"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3934\/Neuroscience.2024009","article-title":"A review of the direct targets of the cannabinoids cannabidiol, \u03949-tetrahydrocannabinol, N-arachidonoylethanolamine and 2-arachidonoylglycerol","volume":"11","author":"Wright","year":"2024","journal-title":"AIMSN"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.611278","article-title":"Cannabidiol acts at 5-HT1A receptors in the human brain: relevance for treating temporal lobe epilepsy","volume":"14","author":"Mart\u00ednez-Aguirre","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111588","article-title":"Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor","volume":"127","author":"Billard","year":"2025","journal-title":"Cell Signalling"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120242","article-title":"Cannabinoids suppress inflammatory and neuropathic pain by targeting \u03b13 glycine receptors","volume":"209","author":"Xiong","year":"2012","journal-title":"J Exp Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.146662","article-title":"Intracellular glycine receptor function facilitates glioma formation in vivo","volume":"127","author":"F\u00f6rstera","year":"2014","journal-title":"J Cell Sci"},{"key":"B109","article-title":"Activation Mechanisms of the NMDA Receptor","volume-title":"Biology of the NMDA Receptor","author":"Blanke","year":"2009"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00169","article-title":"The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia","volume":"4","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2014","journal-title":"Front Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13195-021-00920-6","article-title":"N-methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA receptors","volume":"13","author":"Rivas-Santisteban","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2021.02.011","article-title":"Metabolic regulation of cell competition","volume":"475","author":"Esteban-Mart\u00ednez","year":"2021","journal-title":"Dev Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032540","article-title":"NMDA receptor and its emerging role in cancer","volume":"24","author":"Gallo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.10.023","article-title":"The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic\u2013ischemic brain damage in mice is mediated by CB2 and adenosine receptors","volume":"37","author":"Castillo","year":"2010","journal-title":"Neurobiol Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bcpt.13997","article-title":"Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and parkinson\u2019s disease and in comorbidity with psychiatric disorders","volume":"134","author":"De F\u00e1tima Dos Santos Sampaio","year":"2024","journal-title":"Basic Clin Pharma Tox"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301375","article-title":"Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids","volume":"32","author":"Carriba","year":"2007","journal-title":"Neuropsychopharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00339","article-title":"The endocannabinoid system as a target in cancer diseases: are we there yet","volume":"10","author":"Moreno","year":"2019","journal-title":"Front Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057620","article-title":"D2 dopamine receptors modulate galpha-subunit coupling of the CB1 cannabinoid receptor","volume":"308","author":"Jarrahian","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: the therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-022-01727-4","article-title":"Cannabinoids as anticancer drugs: current status of preclinical research","volume":"127","author":"Hinz","year":"2022","journal-title":"Br J Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17305\/bjbms.2018.3532","article-title":"Cannabinoids in cancer treatment: therapeutic potential and legislation","volume":"19","author":"Dari\u0161","year":"2019","journal-title":"Bosn J Basic Med Sci"},{"key":"B122","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41392-022-00918-y","article-title":"Cannabis suppresses antitumor immunity by inhibiting JAK\/STAT signaling in T cells through CNR2","volume":"7","author":"Xiong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997115","article-title":"Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells","volume":"13","author":"Sarsembayeva","year":"2022","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2022.11.022","article-title":"The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief","volume":"180","author":"Waissengrin","year":"2023","journal-title":"Eur J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0383","article-title":"Cannabis impacts tumor response rate to nivolumab in patients with advanced Malignancies","volume":"24","author":"Taha","year":"2019","journal-title":"Oncologist"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092447","article-title":"Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome","volume":"12","author":"Bar-Sela","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15064","article-title":"The effect of concomitant cannabinoids during immune checkpoint inhibitor treatment of advanced stage Malignancy","volume":"38","author":"Biedny","year":"2020","journal-title":"JCO"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.04.013","article-title":"Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer","volume":"13","author":"Sun","year":"2023","journal-title":"J Pharm Anal"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0902","article-title":"Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS\u2013STING Pathway in Triple-Negative Breast Cancer Cells","volume":"12","author":"Kim","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218035","article-title":"Cannabinoids inhibited pancreatic cancer via P-21 activated kinase 1 mediated pathway","volume":"21","author":"Yang","year":"2020","journal-title":"IJMS"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205142","article-title":"Use of cannabis and cannabinoids for treatment of cancer","volume":"14","author":"Cherkasova","year":"2022","journal-title":"Cancers"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023003","article-title":"High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer","volume":"6","author":"Gustafsson","year":"2011","journal-title":"PloS One"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16383","article-title":"Single nucleotide polymorphisms in the cannabinoid CB 2 receptor: molecular pharmacology and disease associations","volume":"181","author":"Foyzun","year":"2024","journal-title":"Br J Pharmacol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13504","article-title":"Genetic polymorphisms of the endocannabinoid system in obesity and diabetes","volume":"21","author":"Doris","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167338","article-title":"Striving toward hyperthermia-free analgesia: lessons from loss-of-function mutations of human TRPV1","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135600","article-title":"Genetic analyses of the endocannabinoid pathway in association with affective phenotypic variants","volume":"744","author":"Lazary","year":"2021","journal-title":"Neurosci Lett"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1130562","article-title":"Understanding the role of the gut microbiome in gastrointestinal cancer: A review","volume":"14","author":"A\u011fag\u00fcnd\u00fcz","year":"2023","journal-title":"Front Pharmacol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.221","article-title":"Human microbiomes in cancer development and therapy","volume":"4","author":"Xia","year":"2023","journal-title":"MedComm"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt300","article-title":"Human gut microbiome and risk for colorectal cancer","volume":"105","author":"Ahn","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250183","article-title":"Training the microbiota to increase immune checkpoint blockade and to reduce toxicity","volume":"53","author":"Rescigno","year":"2023","journal-title":"Eur J Immunol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature23874","article-title":"Commensal bacteria make GPCR ligands that mimic human signalling molecules","volume":"549","author":"Cohen","year":"2017","journal-title":"Nature"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010185","article-title":"Beneficial effects of akkermansia muciniphila are not associated with major changes in the circulating endocannabinoidome but linked to higher mono-palmitoyl-glycerol levels as new PPAR\u03b1 Agonists","volume":"10","author":"Depommier","year":"2021","journal-title":"Cells"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020872","article-title":"Buds and bugs: A fascinating tale of gut microbiota and cannabis in the fight against cancer","volume":"25","author":"Al-Khazaleh","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.867267","article-title":"The microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism","volume":"16","author":"Srivastava","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"B147","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12974-023-02729-6","article-title":"Cannabinoids modulate the microbiota\u2013gut\u2013brain axis in HIV\/SIV infection by reducing neuroinflammation and dysbiosis while concurrently elevating endocannabinoid and indole-3-propionate levels","volume":"20","author":"McDew-White","year":"2023","journal-title":"J Neuroinflamm"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121702","article-title":"Medicinal cannabis and the intestinal microbiome","volume":"17","author":"Vitetta","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01579-x","article-title":"Cannabinoid formulations and delivery systems: current and future options to treat pain","volume":"81","author":"Stella","year":"2021","journal-title":"Drugs"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7742","article-title":"Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids","volume":"37","author":"Reddy","year":"2023","journal-title":"Phytotherapy Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1143835","article-title":"Age-related modifications in CYP-dependent drug metabolism: role of stress","volume":"14","author":"Konstandi","year":"2023","journal-title":"Front Endocrinol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020972208","article-title":"Reduction in tamoxifen metabolites endoxifen and N-desmethyltamoxifen with chronic administration of low dose cannabidiol: A CYP3A4 and CYP2D6 drug interaction","volume":"35","author":"Parihar","year":"2022","journal-title":"J Pharm Pract"},{"key":"B153","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s13205-021-03102-1","article-title":"Cannabis with breast cancer treatment: propitious or pernicious","volume":"12","author":"Schoeman","year":"2022","journal-title":"3 Biotech"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168688","article-title":"Tamoxifen sensitizes acute lymphoblastic leukemia cells to cannabidiol by targeting cyclophilin-D and altering mitochondrial ca2+ Homeostasis","volume":"22","author":"Olivas-Aguirre","year":"2021","journal-title":"IJMS"},{"key":"B155","doi-asserted-by":"publisher","first-page":"20622","DOI":"10.1038\/s41598-020-77674-y","article-title":"Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma","volume":"10","author":"Go","year":"2020","journal-title":"Sci Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060848","article-title":"Cannabinoid receptor 1 agonist ACEA and cannabinoid receptor 2 agonist GW833972A attenuates cell-mediated immunity by different biological mechanisms","volume":"12","author":"Takheaw","year":"2023","journal-title":"Cells"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9611-3","article-title":"CB2-selective cannabinoid suppresses T-cell activities and increases tregs and IL-10","volume":"10","author":"Robinson","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09912-z","article-title":"[amp]]Delta;9-tetrahydrocannabinol (THC) impairs CD8+ T cell-mediated activation of astrocytes","volume":"15","author":"Henriquez","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9603-3","article-title":"Effects of cannabinoids on T-cell function and resistance to infection","volume":"10","author":"Eisenstein","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/iji.12517","article-title":"HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started","volume":"48","author":"Ivanova","year":"2021","journal-title":"Int J Immunogenetics"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982082","article-title":"Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours","volume":"13","author":"Dada","year":"2023","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1296906","article-title":"Cannabinoids and the endocannabinoid system in immunotherapy: helpful or harmful","volume":"13","author":"Sarsembayeva","year":"2023","journal-title":"Front Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1965319","article-title":"Monoacylglycerol lipase deficiency in the tumor microenvironment slows tumor growth in non-small cell lung cancer","volume":"10","author":"Kienzl","year":"2021","journal-title":"OncoImmunology"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-04002-6","article-title":"Hypothalamic endocannabinoids in obesity: an old story with new challenges","volume":"78","author":"Miralpeix","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114533730","article-title":"Endocannabinoid regulation in human endometrium across the menstrual cycle","volume":"22","author":"Scotchie","year":"2015","journal-title":"Reprod Sci"},{"key":"B168","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","article-title":"Enhanced endocannabinoid tone as a potential target of pharmacotherapy","volume":"204","author":"Toczek","year":"2018","journal-title":"Life Sci"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2016-0346","article-title":"Cannabinoid signaling in health and disease","volume":"95","author":"Lu","year":"2017","journal-title":"Can J Physiol Pharmacol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2124","article-title":"FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma","volume":"30","author":"Patel","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086102","article-title":"VISTA expression and patient selection for immune-based anticancer therapy","volume":"14","author":"Martin","year":"2023","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi7418","article-title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses","volume":"9","author":"Ta","year":"2024","journal-title":"Sci Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00262-024-03701-w","article-title":"The VISTA\/VSIG3\/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma","volume":"73","author":"Olbromski","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B179","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol Ther - Oncolytics"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.960852","article-title":"Implications of NKG2A in immunity and immune-mediated diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/2326-6066.CIR-23-0568","article-title":"ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms","volume":"12","author":"Tian","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004859","article-title":"BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression","volume":"10","author":"Mandel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1421092","article-title":"MHC1\/LILRB1 axis as an innate immune checkpoint for cancer therapy","volume":"15","author":"Hu","year":"2024","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401528","article-title":"From mechanism to therapy: the journey of CD24 in cancer","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41419-019-1593-2","article-title":"Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia","volume":"10","author":"Berrazouane","year":"2019","journal-title":"Cell Death Dis"},{"key":"B187","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41583-022-00611-7","article-title":"TRP channels: A journey towards a molecular understanding of pain","volume":"23","author":"Rosenbaum","year":"2022","journal-title":"Nat Rev Neurosci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1497829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:09:19Z","timestamp":1741140559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1497829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":187,"alternative-id":["10.3389\/fimmu.2025.1497829"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1497829","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1497829"}}